TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis

Expert Opinion on Biological Therapy

Volumn 13, Issue 4, 2013, Pages 469-473

  Saraceno, Rosita ^a   Pietroleonardo, Lucia ^a   Mazzotta, Annamaria ^a   Zangrilli, Arianna ^a   Bianchi, Luca ^a   Chimenti, Sergio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Adalimumab; Etanercept; Infliximab; Nail psoriasis; NAPSI

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENITO URINARY INFECTION; HERPES ZOSTER; HUMAN; INFUSION; INFUSION REACTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAIL PSORIASIS; OTITIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; NAIL DISEASES; PSORIASIS; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAIL DISEASES; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879586154     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.736960     Document Type: Article

References (19)

1. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27
2. Gudjonsson JE, Karason A, Antonsdottir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002;118:362-5
3. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked. Rheumatology 2004;43:790-4
4. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301-5
5. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nail associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996;193:300-3
6. De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000;25:357-62
7. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open prospective study. Br J Dermatol 2003;149:1207-9
8. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60-7
9. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
10. Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52:736-7
11. Nijsten T, Wakkee M. Psocare: italy shows the way in postmarketing studies. Dermatology 2008;217:362-4
12. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:1-70
13. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019
14. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12
15. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biological therapy for psoriasis. Clin Ther 2003;25:2487-505
16. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010;24(5):530-4
17. Rallis E, Stavropoulou E, Rigopoulos D, Verros C. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008;35:544-5
18. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23(8):896-904
19. Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat 2012; [Epub ahead of print]